Review Article
Volume 8 Issue 11 - 2021
Diabetic Related Cardiomyopathy, Pathophysiology, Diagnosis and Potential Treatments
Hanan B Albackr*
Associate Professor of Medicine, Cardiology Consultant, King Fahad Cardiac Center, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia
*Corresponding Author: Hanan B Albackr, Associate Professor of Medicine, Cardiology Consultant, King Fahad Cardiac Center, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Received: September 23, 2021; Published: October 29, 2021


Patients with diabetes mellitus are at increased risk of heart failure irrespective of presence of other heart failure causes like CAD or hypertension. This cardiomyopathy is called diabetic cardiomyopathy (DCM), the detection of which is challenging since most of diabetic patients have other risk factors for developing heart failure. The exact causing pathological mechanism of DCM is unknown but possible mechanisms are related mainly to hyperglycemia leading to many changes like increase free fatty acids, microvascular disease, cellular fibrosis and apoptosis. There is no specific treatment to patients with heart failure related to DMC. Currently there are new medical treatment for type II DM like GLP-1 receptor agonists (GLP-1RA) and Sodium-glucose transporter type 2 (SGLT2) inhibitors that has been shown to decrease the risk of atherosclerotic cardiac diseases in diabetic patients and subsequently heart failure.

Keywords: Diabetes Mellitus; Cardiomyopathy; Pathophysiology


  1. Elliott P., et al. “Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardia land Pericardial Diseases”. European Heart Journal 29 (2008): 270-276.
  2. Petar M Seferovic´and Walter J Paulus. “Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes”. European Heart Journal 36 (2005): 1718-1727.
  3. Pascal De Groote., et al. “Impact of diabetes mellitus on long-term survival in patients with congestive heart failure”. European Heart Journal 25 (2004): 656-662.
  4. Dries DL., et al. “Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction”. Journal of the American College of Cardiology 38 (2001): 421-428.
  5. Varela-Roman A., et al. “Influence of diabetes on the survival of patients hospitalized with heart failure: a 12-year study”. European Journal of Heart Failure 7 (2005): 859-864.
  6. Christine MeindlID., et al. “The role of diabetes in cardiomyopathies of different etiologies-Characteristics and 1-year follow-up results of the EVITA-HF registry”. PLoS One 15 (2020): e0234260.
  7. Andersson C., et al. “Long-term impact of diabetes in patients hospitalized with ischemic and non-ischemic heart failure”. Scandinavian Cardiovascular Journal 44 (2010): 37-44.
  8. Frieler RA and Mortensen RM. “Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling”. Circulation 131 (2015): 1019-1030.
  9. Michael Domanski., et al. “The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial”. Journal of the American College of Cardiology 42 (2003): 914-922.
  10. Rubler S., et al. “New type of cardiomyopathy associated with diabetic glomerulosclerosis”. The American Journal of Cardiology 30 (1972): 595-602.
  11. V Palmieri., et al. “Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects”. Hypertension Genetic Epidemiology Network (Hyper-GEN) study. Circulation 103 (2001): 102-107.
  12. Poirier P., et al. “Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy”. Diabetes Care 24 (2001): 5-10.
  13. Fang ZY., et al. “Screening for heart disease in diabetic subjects”. American Heart Journal 149 (2005): 349-354.
  14. Jensen MT., et al. “Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: The Thousand and 1 Study”. Diabetologia 57 (2014): 672-680.
  15. Ashish Aneja., et al. “Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options”. The American Journal of Medicine 121 (2008): 748-757.
  16. A J Liedtke., et al. “Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium”. Circulation Research 62 (1998): 535-542.
  17. Y Yazaki., et al. “Assessment of myocardial fatty acid abnormalities in patients with idiopathic dilated cardiomyopathy using I123 BMIPP SPECT: correlation with clinicopathological findings and clinical course”. Heart 81 (1999): 153-159.
  18. F Fiordaliso., et al. “Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death”. Diabetes 50 (2001): 2363-2375.
  19. S Chen., et al. “Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors”. Journal of Molecular and Cellular Cardiology 32 (2000): 1621-1629.
  20. Zieman SJ and Kass DA. “Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease”. Drugs 64 (2004): 459-470.
  21. K Mizushige., et al. “Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulinresistant prediabetic stage of a type II diabetic rat model”. Circulation 101 (2000): 899-907.
  22. J Y Park., et al. “Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation”. Diabetes 49 (2000): 1239-1248.
  23. Hattori Y., et al. “Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta”. American Journal of Physiology 261 (1991): 1086-1094.
  24. Adameova A and Dhalla NS. “Role of microangiopathy in diabetic cardiomyopathy”. Heart Failure Reviews 19 (2014): 25-33.
  25. J D Bisognano., et al. “Myocardial directed overexpression of the human (1)-adrenergic receptor in transgenic mice”. Journal of Molecular and Cellular Cardiology 32 (2000): 817-830.
  26. Khatter JC., et al. “Myocardial angiotensin II (Ang II) receptors in diabetic rats”. Annals of the New York Academy of Sciences 793 (1996): 466-472.
  27. Liu X., et al. “Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes”. Annals of the New York Academy of Sciences 1084 (2006): 141-154.
  28. Cai L., et al. “Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy”. Journal of the American College of Cardiology 48 (2006): 1688-1697.
  29. Kwon SH., et al. “H (2)O (2) regulates cardiac myocyte phenotype via concentration dependent activation of distinct kinase pathways”. Journal of Molecular and Cellular Cardiology 35 (2003): 615-621.
  30. Koya D and King GL. “Protein kinase C activation and the development of diabetic complications”. Diabetes 47 (1998): 859-866.
  31. Zhao XY., et al. “Decreased cardiac sarcoplasmic reticulum Ca2 -ATPase activity contributes to cardiac dysfunction in streptozotocin-induced diabetic rats”. The Journal of Physiology and Biochemistry 62 (2006): 1-8.
  32. Pierce GN and Dhalla NS. “Cardiac myofibrillar ATPase activity in diabetic rats”. Journal of Molecular and Cellular Cardiology 13 (1981): 1063-1069.
  33. Barrans JD., et al. “Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray”. American Journal of Pathology 160 (2002): 2035-2043.
  34. Jweied EE., et al. “Depressed cardiac myofilament function in human diabetes mellitus”. The American Journal of Physiology-Heart and Circulatory Physiology 289 (2005): 2478-283.
  35. Bertoni PD., et al. “Altered diastolic function of the left ventricle in juvenile diabetes. Computerized echocardiographic study”. Italian Journal of Cardiology 14 (1984): 839-846.
  36. Venco A., et al. “Echocardiographic features of hypertensive-diabetic heart muscle disease”. Cardiology 74 (1987): 28-34.
  37. H von Bibra., et al. “Augmentation of myocardial function by improved glycemic control in patients with type 2 diabetes mellitus”. Deutsche Medizinische Wochenschrift 132 (2007): 729-734.
  38. P Di Bonito., et al. “Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging”. Diabetic Medicine 22 (2005): 1720-1725.
  39. Ponikowski P., et al. “(2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC”. European Journal of Heart Failure 18 (2016): 891-975.
  40. WRITING COMMITTEE MEMBERS, ACC/AHA TASK FORCE MEMBERS.”2016 ACC/AHA/ HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/ AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America”. Journal of Cardiac Failure 22 (2016): 659-669.
  41. Ewa Konduracka., et al. “Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy”. European Heart Journal 28 (2007): 2465-2471.
  42. Inga Thrainsdottir., et al. “Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure”. Diabetes and Vascular Disease Research 1 (2004): 40-43.
  43. Eurich DT., et al. “Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients”. Circulation: Heart Failure 6 (2013): 395-402.
  44. “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study”. Lancet 352 (1998): 837-853.
  45. John A Dormandy., et al. “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial”. Lancet 366 (2005): 1279-1289.
  46. Jennifer B Green., et al. “Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes”. The New England Journal of Medicine 373 (2015): 232-242.
  47. Li L., et al. “Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies”. BMC Cardiovascular Disorder 16 (2016): 91.
  48. Bernard Zinman., et al. EMPA-REG OUTCOME Investigators. “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes”. New England Journal of Medicine 373 (2015): 2117-2128.
  49. Bruce Neal., et al. CANVAS Program Collaborative Group. “Canagliflozin and cardiovascular and renal events in type 2 diabetes”. New England Journal of Medicine 377 (2017): 644-657.
  50. Faiez Zannad 1., et al. “Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial”. Lancet 385 (2015): 2067-2076.
  51. Stefan D Anker 1., et al. “Empagliflozin in Heart Failure with a Preserved Ejection Fraction, the EMPEROR-Preserved Trial Investigators”. New England Journal of Medicine161 (2021): 451-1461.
Citation: Hanan B Albackr. “Diabetic Related Cardiomyopathy, Pathophysiology, Diagnosis and Potential Treatments”. EC Cardiology 8.11 (2021): 18-29.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 13, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.